-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to Wind data, as of now, a total of 386 listed companies in the Shenwan pharmaceutical and biological industry have released their 2021 annual reports, of which 244 companies have annual operating income of more than 1 billion yuan in 2021, and 255 have a net profit of more than 100 million yuan.
The overall performance was brighter than the previous year
.
According to statistics, among the 386 listed pharmaceutical and biological companies, nearly 300 listed companies plan to distribute cash dividends, reaching 288, and 16 of them have a total dividend of more than 100 million yuan
.
The 16 pharmaceutical companies that distribute dividends include Zhendong Pharmaceutical, Yiqiao Shenzhou, Yunnan Baiyao, Daan Gene, WuXi AppTec, Fosun Pharma, etc.
, including Zhendong Pharmaceutical, Yunnan Baiyao, Daan Gene, WuXi AppTec, The amount of cash dividends such as Fosun Pharma has exceeded 1 billion yuan
.
Specifically, Zhendong Pharmaceutical plans to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares based on the total share capital of 1.
027 billion shares at the end of 2021, with a total cash dividend of 2.
774 billion yuan
.
The amount of cash dividends is about 2.
77 billion yuan
.
It is worth mentioning that the company's total cash dividends exceeded the net profit attributable to shareholders of the parent company in 2021
.
The 2021 annual report shows that Zhendong Pharmaceutical's net profit attributable to shareholders of listed companies is 2.
617 billion yuan
.
According to public information, Zhendong Pharmaceutical's main business is the research and development, production and sales of vitamins, mineral preparations, traditional Chinese medicines, innovative drugs and other products
.
Although Yunnan Baiyao's net profit in 2021 will drop by 49.
17%, the dividend is still not "soft".
It plans to distribute a cash dividend of 16.
00 yuan (tax included) to all shareholders for every 10 shares, and send 4 bonus shares (tax included)
.
It is reported that 2021 will be the first time in nearly 20 years that Yunnan Baiyao has experienced a decline in its annual net profit
.
Compared with the cash dividends distributed per 10 shares in previous years, Yunnan Baiyao's dividends have also decreased
.
From 2018 to 2020, the company will distribute cash dividends of 20 yuan, 30 yuan, and 39 yuan for every 10 shares, without bonus shares
.
According to public information, Yunnan Baiyao is mainly engaged in companies engaged in chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, and biological products
.
WuXi PharmaTech disclosed in its 2021 annual report in March that the company will achieve operating income of 22.
902 billion yuan in 2021, a year-on-year increase of 38.
50%; net profit of 5.
097 billion yuan, a year-on-year increase of 72.
19%; basic earnings per share of 1.
75 yuan
.
At the same time, the company issued a dividend plan, which proposed to distribute a cash dividend of 5.
1740 yuan (tax included) for every 10 shares
.
The company's main business is to provide integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, mainly involving five sectors: chemical business, testing business, biology business, cell and gene therapy CTDMO business, and domestic new drug R&D service business.
, the service scope covers the entire process from concept generation to commercial production, and the service area includes China, the United States, Europe and other regions
.
Of course, there are also a number of listed pharmaceutical and biological companies that choose not to pay dividends
.
Among them, 7 listed companies achieved negative net profit attributable to shareholders of listed companies last year, and there are conditions for no dividends
.
Listed companies such as Xinhua Pharmaceutical did not distribute dividends when they realized the net profit attributable to shareholders of the parent company exceeded 100 million yuan
.
From the perspective of the industry, from the perspective of long-term development, the amount of dividends paid by listed pharmaceutical and biological companies depends on the stage and industry attributes of the subdivided industries.
In relatively mature industries and subdivision industries that do not require much R&D investment, dividends will naturally be higher.
Brilliant"
.
As far as the domestic pharmaceutical and biological industry is concerned, most sub-sectors, including in vitro testing, are still in a period of rapid growth.
Therefore, the growth capability is more attractive than dividends
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The overall performance was brighter than the previous year
.
According to statistics, among the 386 listed pharmaceutical and biological companies, nearly 300 listed companies plan to distribute cash dividends, reaching 288, and 16 of them have a total dividend of more than 100 million yuan
.
The 16 pharmaceutical companies that distribute dividends include Zhendong Pharmaceutical, Yiqiao Shenzhou, Yunnan Baiyao, Daan Gene, WuXi AppTec, Fosun Pharma, etc.
, including Zhendong Pharmaceutical, Yunnan Baiyao, Daan Gene, WuXi AppTec, The amount of cash dividends such as Fosun Pharma has exceeded 1 billion yuan
.
Specifically, Zhendong Pharmaceutical plans to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares based on the total share capital of 1.
027 billion shares at the end of 2021, with a total cash dividend of 2.
774 billion yuan
.
The amount of cash dividends is about 2.
77 billion yuan
.
It is worth mentioning that the company's total cash dividends exceeded the net profit attributable to shareholders of the parent company in 2021
.
The 2021 annual report shows that Zhendong Pharmaceutical's net profit attributable to shareholders of listed companies is 2.
617 billion yuan
.
According to public information, Zhendong Pharmaceutical's main business is the research and development, production and sales of vitamins, mineral preparations, traditional Chinese medicines, innovative drugs and other products
.
Although Yunnan Baiyao's net profit in 2021 will drop by 49.
17%, the dividend is still not "soft".
It plans to distribute a cash dividend of 16.
00 yuan (tax included) to all shareholders for every 10 shares, and send 4 bonus shares (tax included)
.
It is reported that 2021 will be the first time in nearly 20 years that Yunnan Baiyao has experienced a decline in its annual net profit
.
Compared with the cash dividends distributed per 10 shares in previous years, Yunnan Baiyao's dividends have also decreased
.
From 2018 to 2020, the company will distribute cash dividends of 20 yuan, 30 yuan, and 39 yuan for every 10 shares, without bonus shares
.
According to public information, Yunnan Baiyao is mainly engaged in companies engaged in chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, and biological products
.
WuXi PharmaTech disclosed in its 2021 annual report in March that the company will achieve operating income of 22.
902 billion yuan in 2021, a year-on-year increase of 38.
50%; net profit of 5.
097 billion yuan, a year-on-year increase of 72.
19%; basic earnings per share of 1.
75 yuan
.
At the same time, the company issued a dividend plan, which proposed to distribute a cash dividend of 5.
1740 yuan (tax included) for every 10 shares
.
The company's main business is to provide integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, mainly involving five sectors: chemical business, testing business, biology business, cell and gene therapy CTDMO business, and domestic new drug R&D service business.
, the service scope covers the entire process from concept generation to commercial production, and the service area includes China, the United States, Europe and other regions
.
Of course, there are also a number of listed pharmaceutical and biological companies that choose not to pay dividends
.
Among them, 7 listed companies achieved negative net profit attributable to shareholders of listed companies last year, and there are conditions for no dividends
.
Listed companies such as Xinhua Pharmaceutical did not distribute dividends when they realized the net profit attributable to shareholders of the parent company exceeded 100 million yuan
.
From the perspective of the industry, from the perspective of long-term development, the amount of dividends paid by listed pharmaceutical and biological companies depends on the stage and industry attributes of the subdivided industries.
In relatively mature industries and subdivision industries that do not require much R&D investment, dividends will naturally be higher.
Brilliant"
.
As far as the domestic pharmaceutical and biological industry is concerned, most sub-sectors, including in vitro testing, are still in a period of rapid growth.
Therefore, the growth capability is more attractive than dividends
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
